Rare CBD hemp strain found

|

Published 11-DEC-2019 10:19 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

BPH Energy Limited (ASX:BPH) investee Patagonia Genetics has acquired the rights to a recently discovered and rare high CBD hemp strain.

Known as the Carmangola Italian Hemp strain, it is an industrial hemp strain derived from Italy and cultivated for more than 15 years.

The hemp seeds are dioecious meaning that both male and female plants can be grown. The strain is mainly grown for fibre production as well as for Cannabidiol (CBD) oil extraction and resin.

The Carmagnola cultivar has a historically low Tetrahydrocannabinol (THC) reading (below 0.5%). THC is the psychoactive element of cannabis that is generally still banned for use in cannabis products in most global markets.

Whilst low in THC, the strain contains a high CBD content of 7-9%, which makes it ideal for CBD resin and oil extraction. This hemp strain is also capable of producing high quality CBD flower.

Researchers spent considerable time cultivating, testing and phenotype searching (phenotypes are the observable physical properties of an organism and include appearance, development, and behaviour) thousands of Carmagnola plants.

Forthwith, the breeder was able to identify a particular phenotype that carries exceptionally high levels of CBD compared to traditional Carmagnola, whilst maintaining THC levels well below 0.3%.

This particular phenotype of Carmagnola carries a cannabinoid profile of 18.4% CBD and 0.11% THC.

This new phenotype discovery was tested by the 'Centro Tecnológico Nacional Agroalimentario Extremadura (CTAEX), a research association inaugurated in January 2001 as a private centre for innovation and agricultural and food technology. CTAEX produced a Certificate of Analysis (COA).

This phenotype appeals to Patagonia due to its low THC.

The THC reading is substantially lower than the United States Department of Agriculture (USDA) THC limit of 0.3%, meaning it can sold worldwide as hemp, with little risk to the cultivator of exceeding THC limits.

Patagonia establishes relationship with Spanish cultivator

Patagonia recently completed due diligence on Gibraltar-based Calpernia Planters Limited, which holds various licenses which permit it to import and export hemp and cannabis related genetic material, but with a limit on THC content of 0.3% or less.

Patagonia has entered into exclusive distribution agreement with Calpernia.

Calpernia director Michael Trinidad has an agreement in place with Calpernia and is contracted to exclusively cultivate their genetics in Spain under his license and supply them. Under current capacity, the licensed Spanish farm can supply feminised seed in the vicinity of 20,000,000-30,000,000 by mid to late 2020, with the ability to scale into 2021 and beyond.

Commercialisation

Under the terms of the distribution deal, Patagonia can immediately begin selling this newly discovered genetic phenotype under Calpernia's hemp license.

It is expected to supply the market with genetic cuttings or clones of this phenotype by Q1 2020 and feminised seeds by Q3 2020.

The Carmangola strain of hemp.
The Carmangola strain of hemp.

Patagonia has already sent the COA results to major grow shops, distributors and licensed producers worldwide and has received significant interest to supply them with genetics for 2020 cultivations.

* Newly discovered phenotypes of the Carmagnola Hemp Cultivar

Exclusive rights

Patagonia has the exclusive global rights to the newly discovered high CBD phenotype of the Carmagnola Hemp variety, through execution of deal with Calpernia.

Under the terms of the deal, Patagonia has agreed to purchase from Calpernia the following minimum volumes of seeds in order to maintain exclusivity:

  • 2020. 3,000,000 seeds;
  • 2021. 10,000,000 seeds; &
  • 2022. 15,000,000 seeds (capped onwards).

Patagonia will update the market as and when it enters material distributions or sale agreements on this particular phenotype.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X